Initiative combines LC-MS with enzyme-based sample preparation and analysis techniques
Photo for illustration purpose only
Thermo Fisher Scientific has joined forces with Genovis in a collaborative research project to develop advanced end-to-end workflows for the preparation, characterisation and monitoring of novel and complex biotherapeutics using liquid chromatography-mass spectrometry (LC-MS).
The initiative brings together Thermo Fisher’s LC-MS technology with the advanced enzyme-based sample preparation and analysis techniques of Genovis.
"With the shift toward large biological entities, companies are aiming to bring to market medicines with greater affinity and efficacy, but these medicines also present an additional level of analytical complexity," said John Rontree, senior director, global marketing and strategy, pharmaceuticals and biopharmaceuticals, Thermo Fisher Scientific.
"By collaborating with Genovis, we plan to develop comprehensive workflows that provide robust and advanced solutions for preparing and assessing complex biotherapeutics."
Expertise from Thermo Fisher’s Global Customer Solution Centers will also help Genovis to determine optimal hardware/software configurations and suitable consumables for critical quality attribute (CQA) analysis of biotherapeutics during the research and development phase.
"We are excited to work with Thermo Fisher Scientific to continue our goal toward more automated analytical workflows," said Fredrick Olsson, chief executive officer at Genovis.
"Through this collaboration, we will be able to develop new products and workflows on world-class instrumentation together with experts from Thermo Fisher’s European Biopharma Customer Solution Center and serve the growing analytical needs of biopharma customers of both companies with meaningful innovations."
The combination of the Thermo Scientific Vanquish Duo UHPLC Systems (with Dual LC workflow) and the Thermo Scientific Chromeleon Chromatography Data System (CDS) Software with the SmartEnzyme technology from Genovis will enable the development of LC-MS-based protocols for O-glycosylation profiling and automated high-throughput workflows for CQA analysis of monoclonal antibodies at the subunit level.